middle.news
Paradigm Secures $27M to Drive Phase 3 Knee Osteoarthritis Breakthrough
8:44am on Tuesday 1st of July, 2025 AEST
•
Healthcare
Read Story
Paradigm Secures $27M to Drive Phase 3 Knee Osteoarthritis Breakthrough
8:44am on Tuesday 1st of July, 2025 AEST
Key Points
USD $27 million convertible note facility secured from Obsidian Global Partners
Initial $7 million tranche drawn to support patient recruitment and trial operations
Funding covers full site activation, 100% patient recruitment, and mid-2026 interim analysis
Convertible note offers strategic flexibility with market-linked conversion prices
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE